SFO
CRL icon

Stokes Family Office’s Charles River Laboratories CRL Stock Holding History

Stokes Family Office’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,599
Closed -$1.29M – 238
2025
Q1 		$1.29M Buy
8,599
+990
+13% +$166K 0.15% 110
2024
Q4 		$1.4M Sell
7,609
-2,190
-22% -$422K 0.15% 101
2024
Q3 		$1.93M Buy
9,799
+1,465
+18% +$304K 0.21% 84
2024
Q2 		$1.72M Buy
8,334
+1,400
+20% +$317K 0.2% 89
2024
Q1 		$1.88M Buy
6,934
+1,840
+36% +$439K 0.23% 86
2023
Q4 		$1.2M Buy
5,094
+659
+15% +$130K 0.16% 101
2023
Q3 		$869K Buy
+4,435
New +$911K 0.1% 140

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Stokes Family Office's CRL Position: Q2 2025 in Review

Stokes Family Office sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 8,599 shares — an estimated $1.29M sold.

Stokes Family Office first reported a position in CRL in Q3 2023 and held it in 7 quarters. The position peaked at $1.93M in Q3 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Stokes Family Office reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Stokes Family Office sold 8,599 Charles River Laboratories shares in Q2 2025, an estimated $1.29M.
  • Stokes Family Office first reported a position in Charles River Laboratories in Q3 2023 and held it in 7 quarters.
  • Stokes Family Office's Charles River Laboratories position peaked at $1.93M in Q3 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Stokes Family Office's 13F filing for Q2 2025, filed 6 Aug 2025.